Information Provided By: 
Fly News Breaks for February 6, 2020
KRTX
Feb 6, 2020 | 05:30 EDT
Mizuho analyst Vamil Divan initiated coverage of Karuna Therapeutics with a Buy rating and $120 price target. The analyst believes the company's KarXT could be the first "truly game-changing" innovation in schizophrenia in decades, given its muscarinic mechanism of action and "impressive" efficacy and safety data to date. Proprietary calls with psychiatrists highlighted how impressed they are with the KarXT Phase 2 data, Divan tells investors in a research note.
News For KRTX From the Last 2 Days
KRTX
Apr 23, 2024 | 08:31 EDT
New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).
